Longevity Health Holdings Inc. (XAGE)
Longevity Health Holdings Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Pittsburgh, PA, US. The stock last traded at $0.28, up 0.00% on the session, giving a market capitalisation of $400,289. On trailing twelve-month figures it carries a trailing P/E of -0.10, a net margin of -380.7%. Its beta of 0.40 implies it has historically moved less than the broad market.
Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Longevity Health Holdings Inc. is most often compared with the following Healthcare names: